Dr. Naon is a board certified pediatric gastroenterology and in Pediatrics in the Division of Gastroenterology, Hepatology and Nutrition at Children's Hospital of Los Angeles. Dr. Naon participates in national multicenter research studies and committees.
Dr. Naon specializes pediatric gastroenterology with a special interest in inflammatory bowel disease.
Technion, Israel Institute of Technology
Rambam Medical Center
University of California Irvine Medical Center: Pediatric Residency
Children's Hospital Los Angeles: Pediatric Gastroenterology
Pediatrics and Pediatric Gastroenterology: American Board of Pediatrics
American Academy of Pediatrics; American Medical Association; North American Society for Pediatric Gastroenterology, Hepatology & Nutrition; American Gastroenterological Association; American College of Gastroenterology
Naon H, Thomas DW. Secretory tumors of the pancreas. In: Wyllie R, Hyams JS, Eds: Pediatric gastrointestinal disease: Pathophysiology, diagnosis, management. Philadelphia, W.B. Saunders Elsevier Inc, Fourth edition 2011.
Peered Review Articles
Bhardwaj V, Harb R and Naon H. Eosinophilic Esophagitis: A Clinicopathological Review. Special Issue on Pediatric Gastroenterology Disorders. Published online, February. Annals of Pediatrics and Child health. ISSN: 2373-9312. 2015: 3 (2)1040
Pietzak M and Naon H. Celiac Disease and Non-Celiac Gluten Sensitivity. Special Issue on Pediatric Gastroenterology Disorders. Published online, February, Annals of Pediatrics and Child health. 2015, ISSN: 2373-9312. 2015: 3(2)1041
Kerkar N and Naon H. Autoimmune Liver Disease in Children. and Child health. Special Issue on Pediatric Gastroenterology Disorders. Published online, February, Annals of Pediatrics and Child health. ISSN: 2373-9312.2015; 2015:3(2)1045
Danialifar T, S. Zhou, Naon H: Intestinal pneumatosis associated with infliximab therapy in a patient with ulcerative colitis. Practical Gastroenterology, April 2016
Ongoing research studies, include:
A Non-Interventional Long-term Post-Marketing Registry of patients treated with Certolizumab Pegol (Cimzia®) for Crohn’ Disease. A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD). Long Term Registry of Multicenter, Prospective study of Pediatric Patients with inflammatory Bowel Disease treated with Remicade. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis. A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with Inflammatory Bowel Disease